View Older Stories View More Recent Stories

Oct 27, 2022 01:00AM argenx Reports Third Quarter 2022 Financial Results and Provides Business Update
Oct 20, 2022 01:00AM argenx to Report Third Quarter 2022 Financial Results and Business Update on October 27, 2022
Sep 21, 2022 01:00AM argenx to Highlight Key Programs from Neuromuscular Franchise at Upcoming Medical Meetings
Sep 21, 2022 01:00AM argenx Submits Biologics License Application to U.S. Food and Drug Administration for Subcutaneous Efgartigimod for Treatment of Generalized Myasthenia Gravis
Sep 8, 2022 02:13PM argenx (ARGX) Appoints Camilla Sylvest to Board of Directors
Sep 8, 2022 02:10PM argenx Appoints Camilla Sylvest to Board of Directors
Aug 31, 2022 01:00AM argenx to Present at Wells Fargo Healthcare Conference
Jul 28, 2022 02:30AM argenx announces Extraordinary General Meeting of Shareholders on September 8, 2022
Jul 28, 2022 01:00AM argenx Reports Half Year 2022 Financial Results and Provides Second Quarter Business Update
Jul 21, 2022 01:00AM argenx to Report Half Year 2022 Financial Results and Second Quarter Business Update on July 28, 2022
Jun 1, 2022 01:00AM argenx to Present at Upcoming Investor Conferences
May 19, 2022 07:00AM argenx Announces Publication of Translational Data of Efgartigimod in Autoimmune Skin Blistering Diseases
May 10, 2022 05:30PM argenx announces results of Annual General Meeting of Shareholders
May 5, 2022 05:45AM argenx (ARGX) Reports Positive Phase 3 Results from ADVANCE Trial of VYVGART
May 5, 2022 01:00AM argenx Reports First Quarter 2022 Financial Results and Provides Business Update
May 5, 2022 01:00AM argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alfa-fcab) in Adults with Primary Immune Thrombocytopenia
May 4, 2022 01:00AM argenx to Present at BofA Securities 2022 Healthcare Conference
Apr 28, 2022 01:00AM argenx to Report First Quarter 2022 Financial Results and Business Update on May 5, 2022
Apr 5, 2022 05:58AM argenx (ARGX) Reports Interim Results from ADAPT+ Open-Label Extension Study Evaluating VYVGART
Apr 5, 2022 01:00AM argenx Presents Interim Results from ADAPT+ Open-Label Extension Study Evaluating VYVGART® (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis at 2022 AAN Annual Meeting
Apr 1, 2022 01:00AM argenx to Present New Data from Generalized Myasthenia Gravis Program at 2022 American Academy of Neurology Annual Meeting
Mar 29, 2022 04:30PM argenx announces Annual General Meeting of Shareholders on May 10, 2022
Mar 22, 2022 02:00AM argenx Announces Positive Topline Phase 3 Data From ADAPT-SC Study Evaluating Subcutaneous Efgartigimod for Generalized Myasthenia Gravis
Mar 3, 2022 01:00AM argenx Reports Full Year 2021 Financial Results and Provides Fourth Quarter Business Update
Feb 28, 2022 01:00AM argenx to Present at the 42nd Annual Cowen Health Care Conference
Feb 24, 2022 01:00AM argenx to Report Full Year 2021 Financial Results and Fourth Quarter Business Update on March 3, 2022
Feb 10, 2022 01:00AM argenx to Present at the 11th Annual SVB Leerink Global Healthcare Conference
Jan 20, 2022 05:53AM argenx (ARGX) Announces VYVGART Approved in Japan for Treatment of Generalized Myasthenia Gravis
Jan 20, 2022 02:00AM argenx Announces VYVGART™ Approval in Japan for the Treatment of Generalized Myasthenia Gravis
Jan 7, 2022 05:59AM argenx (ARGX) Announces Strategic Priorities for 2022
Jan 7, 2022 01:00AM argenx Highlights Strategic Priorities for 2022
Jan 3, 2022 01:00AM argenx to Present at 40th Annual J.P. Morgan Healthcare Conference
Dec 20, 2021 06:30AM Zai Lab (ZLAB) Partner argenx Announces FDA Approval of VYVGART in Generalized Myasthenia Gravis
Dec 20, 2021 05:46AM argenx (ARGX) Announces FDA Approval of VYVGART in Generalized Myasthenia Gravis
Dec 17, 2021 06:09PM Zai Lab Partner argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis
Dec 17, 2021 05:09PM argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis
Nov 10, 2021 01:00AM argenx to Present at Upcoming Investor Conferences
Oct 28, 2021 01:00AM argenx Reports Third Quarter 2021 Financial Results and Provides Business Update
Oct 21, 2021 01:00AM argenx to Report Third Quarter 2021 Financial Results and Business Update on October 28, 2021
Aug 4, 2021 01:00AM argenx to Present at 2021 Wedbush PacGrow Virtual Healthcare Conference
Jul 29, 2021 01:00AM argenx Reports Half Year 2021 Financial Results and Provides Second Quarter Business Update
Jul 22, 2021 01:00AM argenx to Report Half Year 2021 Financial Results and Second Quarter Business Update on July 29, 2021
Jul 14, 2021 01:00AM argenx to Host Virtual R&D Day on July 20, 2021
Jun 17, 2021 06:09AM argenx (ARGX) announces publication of Phase 3 ADAPT trial results of efgartigimod for the treatment of generalized myasthenia gravis in The Lancet Neurology
Jun 16, 2021 06:30PM argenx announces publication of Phase 3 ADAPT trial results of efgartigimod for the treatment of generalized myasthenia gravis in The Lancet Neurology
Jun 1, 2021 06:59AM argenx (ARGX) Names Karl Gubitz CFO
Jun 1, 2021 04:01AM argenx Appoints Karl Gubitz as Chief Financial Officer
Jun 1, 2021 01:00AM argenx to Present at Upcoming Investor Conferences
May 14, 2021 01:00AM argenx Reports First Quarter 2021 Financial Results and Provides Business Update
May 11, 2021 05:00AM argenx announces results of Annual General Meeting of Shareholders
View More Recent Stories View Older Stories